Loading…
Chinese pharma company known for pediatric and OTC medicines, including cold/fever remedies for children.
Chinese pharma company known for pediatric and OTC medicines, including cold/fever remedies for children.
Moat: narrow (brand). Recognized consumer brand in China's pediatric OTC medicine segment.
Headquarters: Hubei, China · Employees: 4,137
Size HUBEI JUMPCAN PHARMACEUTICAL (600566.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $4.05B, the 633rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥29.28 on 6 Nov 2026.
Performance Over six months the shares gained 5.7%, against +4.0% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue fell 3.6% over the last twelve months (peer median +7.9%); the operating margin is 31.7% (peer median 15.7%).
Valuation It trades at 14.9× forward earnings against a peer median of 22.2× (3rd cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 36.8 points above its cost of capital (5.0% WACC).
Next results Next results expected around 12 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥5.92B | CN¥6.14B | CN¥7.92B | CN¥9.51B | CN¥8.86B |
| Revenue growth | — | -22% | -17% | +7% | — |
| Gross profit | CN¥4.96B | CN¥4.71B | CN¥6.14B | CN¥7.60B | CN¥7.19B |
| EBITDA | n/a | CN¥2.16B | CN¥2.73B | CN¥3.19B | CN¥2.57B |
| Net income | CN¥1.82B | CN¥1.78B | CN¥2.53B | CN¥2.82B | CN¥2.17B |
| Free cash flow | CN¥1.47B | CN¥1.29B | CN¥2.09B | CN¥3.24B | CN¥2.44B |
| Capital expenditure | CN¥260M | CN¥95.9M | CN¥174M | CN¥302M | CN¥244M |
| Total debt | CN¥1.44B | CN¥912M | CN¥1.16B | CN¥1.58B | CN¥733M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | $4.05B | +6% | -4% | 32% | 14.9× | -11.5% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | $2.19B | -3% | -10% | 24% | 15.7× | -2.5% |
| Guangzhou Baiyunshan Pharmaceutical 600332.SS | $4.61B | -11% | +1% | 3% | 13.3× | -0.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600566.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.5% | +6.2% | 6th highest of 21 |
| 6-month return | +5.7% | +4.0% | 9th highest of 21 |
| Distance from 52-week high | -1.3% | -22.9% | 2nd highest of 21 |
| Revenue growth (TTM) | -3.6% | +7.9% | 5th lowest of 20 |
| Operating margin | 31.7% | 15.7% | 3rd highest of 18 |
| Forward P/E | 14.9× | 22.2× | 3rd cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -11.5% | 5.0% | least demanding of 16 |
| Growth delivered (Del g) | +0.3% | +7.5% | 3rd lowest of 16 |
| Hurdle (Req g minus delivered) | -11.8 pp | -2.7 pp | 5th least demanding of 16 |
| ROIC minus cost of capital | +36.8 pp | +7.6 pp | 2nd highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 14.9× | -11.5% | +0.3% |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 38.6× | 20.2% | +6.2% |
| Shanghai Junshi Biosciences 688180.SS | China | $4.06B | -24% | +29% | -15% | n/a | n/a | n/a |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $4.11B | +4% | -13% | 20% | 31.4× | 17.8% | -5.8% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 17.8× | n/a | n/a |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 32.9× | 0.7% | +192.5% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 22.3× | 1.5% | +12.1% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% | +5.9% |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 15.6× | -5.2% | +3.2% |
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| HanmiPharm 128940.KS | South Korea | $4.36B | +2% | +14% | 16% | 16.8× | 5.0% | +7.5% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.37B | +7% | +25% | 25% | 32.2× | 23.8% | +13.8% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% | +7.8% |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 25.1× | 6.3% | +4.5% |
| Livzon Pharmaceutical 000513.SZ | China | $3.71B | -4% | -14% | 19% | 16.9× | -9.8% | +2.7% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| Definium Therapeutics DFTX | United States | $4.47B | +51% | n/a | n/a | n/a | n/a | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $4.47B | -34% | +227% | 74% | 46.9× | 3.3% | +45.1% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.47B | +33% | +21% | 16% | 33.9× | 14.9% | +12.7% |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 21.5× | 16.7% | +19.4% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 4.0× | -4.5% | -1.0% |